Alexion and Amgen announce eculizumab settlement

May 29, 2020

In a filing to the Securities and Exchange Commission, Alexion announces it has settled its eculizumab dispute with Amgen. Under the agreement, Amgen will receive a non-exclusive, royalty-free license to market its product from 01 March 2025.

Print Page Mail Article